Cancer Treatment and Research Center (CTIC), Luis Carlos Sarmiento Angulo Foundation; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Urol Oncol. 2024 Dec;42(12):455.e1-455.e8. doi: 10.1016/j.urolonc.2024.07.012. Epub 2024 Aug 26.
Primary retroperitoneal lymph node dissection (pRPLND) is a treatment option for clinical stage (CS) II testicular germ cell tumors (TGCTs) and CS I with retroperitoneal relapse. Increasing raw lymph node yield during pRPLND has been associated a decreased relapse risk. However, this metric has limitations due to variations in surgical templates and specimen processing methods. We aimed to evaluate the lymph node density (LND), which is the ratio of positive lymph nodes to the total number of nodes removed, as a prognostic marker for relapse after pRPLND.
We reviewed all patients who underwent pRPLND at the Princess Margaret Cancer Centre between 1990 and 2022. The primary endpoint was relapse-free survival (RFS). RFS was calculated using the Kaplan-Meier product-limit method. The log-rank test was used to assess the impact of LND, and recursive binary partitioning was used to determine the threshold LND that provides optimum separation in RFS.
In this study, 178 patients were treated with pRPLND. A total of 137 (77%) patients had pathological evidence of nodal metastasis, 96 were treated with open RPLND, and 41 with robotic RPLND. The median number of lymph nodes harvested was 32 (IQR 23-43) and median total positive nodes was 2 (IQR 1-36). This translated into a median LND of 3.1% (IQR 1.7-57.1). There was no significant difference in the LND between robotic and open approaches (P = 0.6664). After a median follow-up of 38.6 months, 11 patients (8.02%) had relapsed. LND was not significantly associated with relapse (HR 1.018, 95% CI, 0.977-1.061). The optimal threshold to dichotomize LND that provides optimum separation in RFS was ≥ 26.75%, however, it did not reach statistical significance (P = 0.0651).
In conclusion, the LND was not associated with RFS after pRPLND in patients with TGCTs. The unique characteristics of TGCTs and the presence of other established risk factors limit the utility of the LND alone in predicting relapse.
原发性腹膜后淋巴结清扫术(pRPLND)是治疗临床分期(CS)II 期睾丸生殖细胞肿瘤(TGCTs)和伴有腹膜后复发的 CS I 期 TGCT 的一种治疗选择。pRPLND 时增加原始淋巴结产量与复发风险降低有关。然而,由于手术模板和标本处理方法的差异,该指标存在局限性。我们旨在评估淋巴结密度(LND),即阳性淋巴结与切除的总淋巴结数之比,作为 pRPLND 后复发的预后标志物。
我们回顾了 1990 年至 2022 年间在玛格丽特公主癌症中心接受 pRPLND 的所有患者。主要终点是无复发生存率(RFS)。RFS 使用 Kaplan-Meier 乘积限法计算。对数秩检验用于评估 LND 的影响,递归二分分割用于确定提供 RFS 最佳分离的 LND 阈值。
在这项研究中,178 名患者接受了 pRPLND 治疗。共有 137 名(77%)患者有淋巴结转移的病理证据,96 名患者接受了开放式 RPLND 治疗,41 名患者接受了机器人 RPLND 治疗。切除的淋巴结中位数为 32(IQR 23-43),总阳性淋巴结中位数为 2(IQR 1-36)。这转化为中位数 LND 为 3.1%(IQR 1.7-57.1)。机器人和开放式方法之间的 LND 无显著差异(P=0.6664)。中位随访 38.6 个月后,11 名患者(8.02%)复发。LND 与复发无显著相关性(HR 1.018,95%CI,0.977-1.061)。最佳阈值为≥26.75%,将 LND 分为两组以在 RFS 中提供最佳分离,但未达到统计学意义(P=0.0651)。
总之,在 TGCT 患者中,pRPLND 后 LND 与 RFS 无关。TGCT 的独特特征和其他已确立的危险因素的存在限制了 LND 单独预测复发的效用。